Navigation Links
Shire plc: Continued Strong Product Sales Performance in Q3: On Track to Deliver Significant 2011 Earnings Growth
Date:10/28/2011

>a)Amortization and asset impairments: Amortization of intangible assets relating to intellectual property rights acquired ($99.6 million), impairment charges to record DAYTRANA assets at fair value less costs to sell ($42.7 million) and tax effect of adjustments;

b)Acquisitions and integration activities: Up-front payment to Acceleron ($45.0 million), acquisition costs are principally costs associated with the acquisition of Movetis ($6.4 million) and tax effect of adjustments;

c)Divestments, reorganizations and discontinued operations: Accelerated depreciation ($18.3 million) and dual running costs ($3.6 million) on the transfer of manufacturing from Owings Mills, gain on sale of product rights relating to the disposal of non core products to Laboratorios Almirall S.A. ($4.1 million), reorganization costs ($23.3 million) on the transfer of manufacturing from Owings Mills and the establishment of an international commercial hub in Switzerland, gain on disposal of the investment in Virochem ($11.1 million) and tax effect of adjustments; and

d)Depreciation: Depreciation of $69.2 million included in Cost of product sales, R&D costs and SG&A costs for US GAAP separately disclosed for the presentation of Non GAAP earnings.


 

Unaudited results for the three months and nine months to September 30, 2011

Non GAAP reconciliation

The following table reconciles US GAAP net cash provided by operating activities to Non GAAP cash generation:

3 months to September 30, 9 months to September 30, 2011 2010 2011 2010 $M $M $M $M Net cash provided by operating activities 178.7 142.0 664.2 612.0 Tax and interest payments, net 117.2 83.6 280.0 301.6 Payments for acquired and in-licensed products - 45.0 - 45.0 Non GAAP cash generation 295.9 270.6 944.2 958.6

The following table reconciles US GAAP net cash provided by operating activities to Non GAAP free cashflow:<
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31

Related biology technology :

1. NHS Northamptonshire Chief Executive John Parkes Accepts Visiting Professorship
2. FDA Approves Shires FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)
3. Shires Quarterly Revenues Grow by 25% to $1 Billion for the First Time
4. Shire Files Lawsuits Against Watson and Roxane for Infringement of VYVANSE(R) (lisdexamfetamine dimesylate) Patents
5. Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)
6. Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse(R) (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder
7. Shire plc: Continued Excellent Performance in Q3, Full Year Earnings Expectations Increased, New Value in Pipeline Emerging
8. Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period
9. Reportlinker Adds Shire plc: PharmaVitae Profile
10. Shire Announces European Approval of VPRIV(R) (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease
11. Shire plc - Statement re ProAmatine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Potential Efficacy in Huntington,s Disease Already Demonstrated, ... Pharmaceuticals,Corp. ("Raptor" or the "Company") (OTC Bulletin ... and Drug Administration ("FDA") has granted,orphan drug ... of Huntington,s disease ("HD"). Cysteamine is currently ...
... for Early Identification of High Risk Patients Early ... Intervention Can Help Prevent Disease Progression, SAN FRANCISCO, ... 68th Scientific Sessions of the American Diabetes Association,(ADA) that ... Diabetes,Risk Test, a first-of-its-kind predictive tool that delivers an ...
... June 6 Bioheart, Inc. (Nasdaq:,BHRT) will host its ... at Chispa Restaurant, located at 11500 NW 41st Street ... EASTERN., Interested parties may listen to the Bioheart, ... (domestic) or (706) 643-0580,(international). To listen to the Annual ...
Cached Biology Technology:Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 2Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 3Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 4Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntington's Disease 5Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 2Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 3Tethys Bioscience Announces Expanded Availability of PreDx(TM) Diabetes Risk Test 4Bioheart, Inc. to Host Annual Meeting of Shareholders on Wednesday, July 30, 2008 2
(Date:12/4/2014)... PALM BEACH GARDENS, Fla. , Dec. 3, ... identity management solutions, today announced that its DigitalPersona ... 4500 fingerprint readers have been deployed throughout ... Carolina , South Carolina ... network headquartered in Southern Pines, North ...
(Date:12/3/2014)... 2014 As part of our commitment to ... pleased to announce the release of a new reader ... the workforce data that they need. The ... by existing readers. Many such devices have serious shortcomings ... technology. Older models force users to navigate numerous complicated ...
(Date:11/21/2014)... , Nov. 19, 2014  Earlier this year ... York College, and one of the most prolific inventors ... that are transmitted from Smartphones to third party agencies. ... and has one of the earliest known patents in ... usage in the military, child care, elder care and ...
Breaking Biology News(10 mins):First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Inception Technologies to Release New Biometric Reader 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... research team led by a Michigan State University professor has discovered ... help treat one of the disease,s most common and potentially blindness-causing ... to blood vessels in the retina that affects up to 80 ... in damage to the nerves found in bone marrow that leads ...
... report that Helicobacter pylori , the only bacterium ... human stomach, directly activates an enzyme in host cells ... including gastric cancer. Chronic infection with H. ... forms of gastric cancer, but researchers have not yet ...
... a growing number of fast food and chain restaurants display ... a study suggests some of this information may be unreliable. ... 18 side dishes and entrees from national sit-down chain restaurants, ... and 10 frozen meals purchased from supermarkets. They compared their ...
Cached Biology News:MSU researcher links diabetic complication, nerve damage in bone marrow 2Team finds link between stomach-cancer bug and cancer-promoting factor 2Team finds link between stomach-cancer bug and cancer-promoting factor 3Study examines calorie information from restaurants, packaged foods 2
... protein A media yield highly purified ... to analysis of other immunoglobulin classes, ... purification. Protein A binds to the ... from mammalian species. This ready-to-use, bottled ...
... bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. ... CHAPSO. Has reduced electrostatic interactions that do ... DEAE-cellulose. Aggregation number: 8-16. Purity: ≥95% ... O. Aggregation number 8 - 16, CMC ...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Goat polyclonal to STMN2 ( Abpromise for all tested applications). Antigen: Synthetic peptide: AKTAMAYKEK, corresponding to C terminal amino acids 2-11 of STMN2. Entrez Gene ID: 11075 Swi...
Biology Products: